Rankings
▼
Calendar
AKBA
Akebia Therapeutics, Inc.
$365M
FY 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$295M
-12.0% YoY
Gross Profit
$231M
78.3% margin
Operating Income
-$378M
-128.2% margin
Net Income
-$385M
-130.6% margin
EPS (Diluted)
$-2.53
Cash Flow
Operating Cash Flow
-$110M
Free Cash Flow
-$111M
Stock-Based Comp.
$24M
Balance Sheet
Total Assets
$644M
Total Liabilities
$397M
Stockholders' Equity
$248M
Cash & Equivalents
$229M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$295M
$335M
-12.0%
Gross Profit
$231M
$190M
+21.6%
Operating Income
-$378M
-$286M
-32.0%
Net Income
-$385M
-$280M
-37.6%
← Q4 2019
All Quarters
Q1 2020 →
AKBA FY 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena